NASDAQ:QGEN - Qiagen Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $34.60 -0.42 (-1.20 %) (As of 12/16/2018 04:00 PM ET)Previous Close$34.60Today's Range$34.47 - $34.8952-Week Range$30.78 - $39.45Volume1.23 million shsAverage Volume997,263 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight. Receive QGEN News and Ratings via Email Sign-up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryLife Sciences Tools & Services SectorN/A Current SymbolNASDAQ:QGEN Previous Symbol CUSIPN7248210 Webwww.qiagen.com Phone+31-77-3556600 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees4,684 Outstanding Shares228,230,000Market Cap$0.00 OptionableOptionable Qiagen (NASDAQ:QGEN) Frequently Asked Questions What is Qiagen's stock symbol? Qiagen trades on the NASDAQ under the ticker symbol "QGEN." How will Qiagen's stock buyback program work? Qiagen declared that its Board of Directors has authorized a stock buyback program on Thursday, February 1st 2018, which authorizes the company to buyback $200,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company's board of directors believes its stock is undervalued. How were Qiagen's earnings last quarter? Qiagen NV (NASDAQ:QGEN) released its earnings results on Monday, October, 29th. The company reported $0.35 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.33 by $0.02. The company earned $377.90 million during the quarter, compared to analysts' expectations of $380.11 million. The company's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.32 earnings per share. View Qiagen's Earnings History. When is Qiagen's next earnings date? Qiagen is scheduled to release their next quarterly earnings announcement on Wednesday, January 30th 2019. View Earnings Estimates for Qiagen. What guidance has Qiagen issued on next quarter's earnings? Qiagen issued an update on its fourth quarter earnings guidance on Monday, October, 29th. The company provided EPS guidance of $0.39-0.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.41. The company issued revenue guidance of +6-7% y/y (Approx $419-423 million), compared to the consensus revenue estimate of $418.87 million.Qiagen also updated its FY 2018 guidance to $1.33-1.34 EPS. What price target have analysts set for QGEN? 12 equities research analysts have issued 12 month price objectives for Qiagen's stock. Their predictions range from $34.00 to $44.00. On average, they anticipate Qiagen's share price to reach $39.1250 in the next twelve months. This suggests a possible upside of 13.1% from the stock's current price. View Analyst Price Targets for Qiagen. What is the consensus analysts' recommendation for Qiagen? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Qiagen. Has Qiagen been receiving favorable news coverage? Press coverage about QGEN stock has trended somewhat positive on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Qiagen earned a news sentiment score of 1.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. Who are Qiagen's key executives? Qiagen's management team includes the folowing people: Manfred E. Karobath, Chairman of the Supervisory Board (Age 76)Peer M. Schatz, Chief Executive Officer, Managing DirectorRoland Sackers, Chief Financial OfficerThomas Schweins, Senior Vice President - Human Resources, Strategy & Marketing ServicesThierry Bernard, Senior Vice President - Molecular Diagnostics Business AreaLaura Furmanski, Senior Vice President - Bioinformatics Business AreaDouglas Liu, Senior Vice President - Global OperationsManuel O. Mendez, Senior Vice President - Global Commercial OperationsStephane Bancel, Independent Supervisory Director (Age 44)Hakan Bjorklund, Supervisory Board Director (Age 61) Who are Qiagen's major shareholders? Qiagen's stock is owned by a number of of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (7.10%), Massachusetts Financial Services Co. MA (5.32%), Deutsche Bank AG (5.06%), Franklin Resources Inc. (4.49%), Vanguard Group Inc. (2.90%) and Vanguard Group Inc (2.90%). Which institutional investors are selling Qiagen stock? QGEN stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Man Group plc, Assenagon Asset Management S.A., JPMorgan Chase & Co., JPMorgan Chase & Co., TIAA CREF Investment Management LLC, Marshall Wace LLP and Exane Asset Management. Which institutional investors are buying Qiagen stock? QGEN stock was bought by a variety of institutional investors in the last quarter, including Capital World Investors, FIL Ltd, First Trust Advisors LP, William Blair Investment Management LLC, American Century Companies Inc., Hardman Johnston Global Advisors LLC, Massachusetts Financial Services Co. MA and SG Americas Securities LLC. How do I buy shares of Qiagen? Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Qiagen's stock price today? One share of QGEN stock can currently be purchased for approximately $34.60. What is Qiagen's official website? The official website for Qiagen is http://www.qiagen.com. How can I contact Qiagen? Qiagen's mailing address is Hulsterweg 82, VENLO, 5912 PL, Netherlands. The company can be reached via phone at +31-77-3556600 or via email at [email protected] MarketBeat Community Rating for Qiagen (NASDAQ QGEN)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 343 (Vote Outperform)Underperform Votes: 441 (Vote Underperform)Total Votes: 784MarketBeat's community ratings are surveys of what our community members think about Qiagen and other stocks. Vote "Outperform" if you believe QGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/16/2018 by MarketBeat.com StaffFeatured Article: Is the Dow Jones Industrial Average (DJIA) still relevant?